CN101389628B - 作为eg5驱动蛋白调节剂的吲哚并吡啶 - Google Patents

作为eg5驱动蛋白调节剂的吲哚并吡啶 Download PDF

Info

Publication number
CN101389628B
CN101389628B CN2007800065292A CN200780006529A CN101389628B CN 101389628 B CN101389628 B CN 101389628B CN 2007800065292 A CN2007800065292 A CN 2007800065292A CN 200780006529 A CN200780006529 A CN 200780006529A CN 101389628 B CN101389628 B CN 101389628B
Authority
CN
China
Prior art keywords
methyl
ethyl
hydroxyl
phenyl
azepines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800065292A
Other languages
English (en)
Chinese (zh)
Other versions
CN101389628A (zh
Inventor
马蒂亚斯·文尼曼
托马斯·贝尔
于尔根·布劳恩格
阿斯特丽德·齐默尔曼
福尔克尔·格克勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4sc Corp
Original Assignee
4sc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4sc Corp filed Critical 4sc Corp
Publication of CN101389628A publication Critical patent/CN101389628A/zh
Application granted granted Critical
Publication of CN101389628B publication Critical patent/CN101389628B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800065292A 2006-02-22 2007-02-21 作为eg5驱动蛋白调节剂的吲哚并吡啶 Expired - Fee Related CN101389628B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06110295 2006-02-22
EP06110295.0 2006-02-22
EP06119038.5 2006-08-16
EP06119038 2006-08-16
PCT/EP2007/051688 WO2007096393A1 (en) 2006-02-22 2007-02-21 Indolopyridines as eg5 kinesin modulators

Publications (2)

Publication Number Publication Date
CN101389628A CN101389628A (zh) 2009-03-18
CN101389628B true CN101389628B (zh) 2013-02-27

Family

ID=37964159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800065292A Expired - Fee Related CN101389628B (zh) 2006-02-22 2007-02-21 作为eg5驱动蛋白调节剂的吲哚并吡啶

Country Status (18)

Country Link
US (1) US8530493B2 (cg-RX-API-DMAC7.html)
EP (3) EP1996592B1 (cg-RX-API-DMAC7.html)
JP (1) JP5349056B2 (cg-RX-API-DMAC7.html)
KR (1) KR101415354B1 (cg-RX-API-DMAC7.html)
CN (1) CN101389628B (cg-RX-API-DMAC7.html)
AR (1) AR059609A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007217560B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708233A2 (cg-RX-API-DMAC7.html)
CA (1) CA2643488C (cg-RX-API-DMAC7.html)
EA (1) EA015150B1 (cg-RX-API-DMAC7.html)
HK (1) HK1205510A1 (cg-RX-API-DMAC7.html)
IL (1) IL193625A (cg-RX-API-DMAC7.html)
MX (1) MX2008010801A (cg-RX-API-DMAC7.html)
NZ (1) NZ571357A (cg-RX-API-DMAC7.html)
TW (1) TWI377207B (cg-RX-API-DMAC7.html)
UA (1) UA96592C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007096393A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200808070B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
DE602005024572D1 (de) 2004-08-18 2010-12-16 4Sc Ag Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
SI1901729T1 (sl) * 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
EP2098524A1 (en) * 2008-03-05 2009-09-09 4Sc Ag Process for preparing enantiomerically pure indolopyrinidines
SI2262493T1 (sl) * 2008-03-07 2015-07-31 Onxeo Dk Branch Of Onxeo S.A. France Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN109467555A (zh) * 2018-06-21 2019-03-15 广东蓝堡生物科技有限公司 一种他达那非衍生物及其制备方法和应用
CN109160914B (zh) * 2018-11-17 2020-06-16 重庆文理学院 一种双吲哚并吡啶类衍生物的合成方法及在抗肿瘤中的应用
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途
CN113577063B (zh) * 2021-08-30 2022-08-16 广州领晟医疗科技有限公司 一种化合物在制备治疗炎性肠病的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004156A1 (en) * 2000-02-24 2005-01-06 President And Fellows Of Harvard College Kinesin inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357122A3 (en) 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19744257B4 (de) 1997-10-07 2004-04-15 Zentaris Gmbh Beta-Carboline und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
AU2002213421A1 (en) 2000-10-03 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
WO2002095361A2 (en) 2001-05-22 2002-11-28 President And Fellows Of Harvard College Identification of anti-protozoal agents
CA2460939C (en) 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
EP2292615A1 (en) 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP4580932B2 (ja) 2003-06-12 2010-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤のプロドラッグ
CN1960725A (zh) 2004-03-15 2007-05-09 Ptc医疗公司 用于抑制血管发生的四环咔啉衍生物
DE602005024572D1 (de) * 2004-08-18 2010-12-16 4Sc Ag Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
AU2006212863A1 (en) 2005-02-10 2006-08-17 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2007144384A1 (en) 2006-06-14 2007-12-21 4Sc Ag Pyrazolopyrimidones
WO2008006883A2 (en) 2006-07-13 2008-01-17 4Sc Ag Benzopyranopyrazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004156A1 (en) * 2000-02-24 2005-01-06 President And Fellows Of Harvard College Kinesin inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
David R Bevan et al.Application of Molecular Modeling to Analysis of Inhibition of Kinesin Motor Proteins of the BimC Subfamily by Monastrol and Related Compounds.《Chemistry & Biodiversity》.2005,第2卷(第11期),1525-1532. *
Nils Sunder-Plassmann et al.Synthesis and biological evaluation of new tetrahydro-β-carbolines as inhibitors of the mitotic kinesin Eg5.《Bioorganic & Medicinal Chemistry》.2005,第13卷(第22期),6094-6111. *

Also Published As

Publication number Publication date
TW200815441A (en) 2008-04-01
EP1996592B1 (en) 2014-08-27
HK1205510A1 (en) 2015-12-18
EP2824105B1 (en) 2021-03-31
EA200801739A1 (ru) 2009-04-28
IL193625A0 (en) 2009-05-04
US20090233902A1 (en) 2009-09-17
IL193625A (en) 2015-01-29
CN101389628A (zh) 2009-03-18
CA2643488A1 (en) 2007-08-30
NZ571357A (en) 2010-11-26
AU2007217560A1 (en) 2007-08-30
AR059609A1 (es) 2008-04-16
UA96592C2 (uk) 2011-11-25
BRPI0708233A2 (pt) 2011-05-24
KR101415354B1 (ko) 2014-07-04
MX2008010801A (es) 2008-09-05
US8530493B2 (en) 2013-09-10
EA015150B1 (ru) 2011-06-30
EP1996592A1 (en) 2008-12-03
CA2643488C (en) 2014-08-05
ZA200808070B (en) 2014-03-26
JP5349056B2 (ja) 2013-11-20
EP2824105A1 (en) 2015-01-14
KR20080098043A (ko) 2008-11-06
AU2007217560B2 (en) 2012-06-28
TWI377207B (en) 2012-11-21
JP2009527533A (ja) 2009-07-30
WO2007096393A1 (en) 2007-08-30
EP3862354A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
CN101389628A (zh) 作为eg5驱动蛋白调节剂的吲哚并吡啶
JP7449843B2 (ja) セストリン-gator2相互作用のモジュレーターおよびその使用
US20090246169A1 (en) Indolopyridines as eg5 kinesin modulators
CN106243100B (zh) 治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法
JP6155026B2 (ja) プロテインキナーゼ阻害のための新規化合物及びその治療的使用
US20110027226A1 (en) Indolopyridines as inhibitors of the kinesin spindle protein (eg5)
CN109789144A (zh) 蛋白激酶调节剂
ES2930081T3 (es) Pirazolopirimidinas sustituidas útiles como inhibidores de quinasas
EP2033962A1 (en) Tetracyclic indolopyridines as EG5 inhibitors
CN110256346A (zh) 具有brd4蛋白抑制作用的菲啶酮类化合物及制备方法和应用
CN114437114A (zh) 二酮哌嗪类天然产物及衍生物的应用、制备与所得衍生物
HK40057521A (en) Indolopyridines as eg5 kinesin modulators
HK1125370A (en) Indolopyridines as eg5 kinesin modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20090318

Assignee: LINK HEALTH Group

Assignor: 4SC Corp.

Contract record no.: 2016990000352

Denomination of invention: Indolopyridines as EG5 kinesin modulators

Granted publication date: 20130227

License type: Exclusive License

Record date: 20160823

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130227

CF01 Termination of patent right due to non-payment of annual fee